Drugs similar to or like Oxford–AstraZeneca COVID-19 vaccine
COVID-19 vaccine developed by Oxford University and AstraZeneca given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. Wikipedia
COVID-19 vaccine developed by the United States National Institute of Allergy and Infectious Diseases , the Biomedical Advanced Research and Development Authority (BARDA), and Moderna. Administered by two 0.5 mL doses given by intramuscular injection given four weeks apart. Wikipedia
Inactivated virus based COVID-19 vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research. In May 2020, Indian Council of Medical Research's (ICMR's) National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine. Wikipedia
Sentences forOxford–AstraZeneca COVID-19 vaccine
- As of 7 January, authorized and approved vaccines have shown efficacies ranging from 62–90% for the Oxford–AstraZeneca vaccine (various dosage regimens) to 95% for the Pfizer-BioNTech COVID‑19 vaccine.
- After the Gates foundation urged the University of Oxford to find a large company partner to get its COVID-19 vaccine to market, the university backed off from its earlier pledge to donate the rights to any drugmaker.
- This would also affect deliveries of the Oxford–AstraZeneca COVID-19 vaccine, which has been provisionally approved by the TGA.
- A report on 9 February 2021 stated that the AstraZeneca COVID-19 vaccine was in short supply due to delays in receiving the expected number of doses.
- On 10 February 2021, South Korea granted its first approval of a COVID-19 vaccine to Oxford–AstraZeneca, allowing the two-shot regimen to be administered to all adults, including the elderly.
- On 17 January, the Government requested early deliveries of the Oxford–AstraZeneca COVID-19 vaccine as discussions to secure early delivery of the vaccine got underway.
- The early projection includes 1.2 million doses of the Pfizer/BioNTech vaccine in Q1 2021 and 336 million doses of the Oxford–AstraZeneca COVID-19 vaccine in first half 2021 to the 145 COVAX facility participants.
- On 22 January, it transpired that AstraZeneca would, after the expected approval of its vaccine by the European Union on 29 January, only be able to deliver 31million doses, instead of the agreed 80million doses.
- The first shipment of 21,600 AstraZeneca COVID-19 vaccines arrived in the Republic of Ireland on 6 February.
- The Moderna vaccine was authorized on 6 January 2021 and the AstraZeneca vaccine was authorized on 29 January 2021.
- On the 25th of January 2021, Handelsblatt published an unsourced story falsely claiming that the Oxford-Astrazeneca Covid-19 vaccine was only 8% effective in over 65's. Astrazeneca and the University of Oxford issued statements denying these claims.
- On February 1, it was confirmed that Uruguay would be supplied with the Oxford–AstraZeneca vaccines, and that with the first batch, 3% of the population would be vaccinated.
- On 16 January 2021, AstraZeneca's COVID-19 vaccine was approved for emergency use in Pakistan as the Chinese vaccine was awaiting approval from the Drug Regulatory Authority of Pakistan (DRAP).
- In January 2021, the government contracted India's Serum Institute to provide 5 million doses of the Oxford–AstraZeneca vaccine.
- The Sputnik V and the BNT162b2 vaccines were the first to receive emergency approvals from ANMAT, On 30 December 2020, the University of Oxford and AstraZeneca's vaccine AZD1222 was also approved for use by ANMAT.
- On 22 January 2021, Sri Lanka's National Medical Regulatory Authority said, they approved the Oxford–Astra-Zeneca vaccine.
- On February 7, it was announced that the Oxford–AstraZeneca COVID-19 vaccine did not work well in protecting clinical trial participants from mild or moderate illness caused by the 501.V2 variant severe acute respiratory syndrome coronavirus 2, also known as B.1.351 lineage.
- The health ministry on 30 January 2021 approved COVID-19 vaccine from AstraZeneca for domestic inoculation.
- One month later, Fernández announced that the vaccine produced by the University of Oxford and AstraZeneca (AZD1222) would begin production alongside Mexico after an agreement with the British pharmaceutical company and the biotechnology company mAbxience.
- On February 9, 2021, the Ministry of Health of the Republic of Azerbaijan allowed clinical studies in the country for the combined use of the Sputnik V vaccine and the vaccine developed by AstraZeneca, stating that the trials would begin before the end of February 2021.
- On 11 February, Fiji approved access to the Oxford–AstraZeneca COVID-19 vaccine for its national COVID-19 vaccination programme.
- One day later, the AZD1222 vaccine developed by University of Oxford and AstraZeneca was also approved in the country.
- On 19 January 2021, Iraq authorized the emergency use of the United Kingdom's Oxford-AstraZeneca vaccine, as well as China's SinoPharm vaccine.
- On 11 February 2021, Saint Vincent and the Grenadines issued an EUA for J&J's vaccine, as well as the Moderna vaccine, the Pfizer–BioNTech vaccine, the Sputnik V vaccine, and the Oxford–AstraZeneca vaccine.
This will create an email alert. Stay up to date on result for: Oxford–AstraZeneca COVID-19 vaccine